Tandem Diabetes Care
TNDM
284 hedge funds and large institutions have $3.24B invested in Tandem Diabetes Care in 2019 Q4 according to their latest regulatory filings, with 58 funds opening new positions, 85 increasing their positions, 101 reducing their positions, and 45 closing their positions.
29% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 45
16% more call options, than puts
Call options by funds: $46.2M | Put options by funds: $39.7M
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
11% more capital invested
Capital invested by funds: $2.93B → $3.24B (+$310M)
7.28% more ownership
Funds ownership: 84.75% → 92.03% (+7.3%)
4% more funds holding
Funds holding: 273 → 284 (+11)
16% less repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 101
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$92.2M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$59.9M |
| 3 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
+$56.1M |
| 4 |
DM
Deerfield Management
New York
|
+$55.9M |
| 5 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$37.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$37.5M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$36.7M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
-$33M |
| 4 |
FAM
Fred Alger Management
New York
|
-$32.5M |
| 5 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$32.4M |
TNDM Hedge Fund Activity: Q4 2019 in Review
284 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Tandem Diabetes Care (TNDM) for Q4 2019, worth a combined $3.24B — up 11% from $2.93B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new TNDM positions and 45 closed out — a net gain of 13 holders — while 85 added to existing stakes and 101 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $92.2M. The largest seller was Renaissance Technologies, cutting an estimated $37.5M.
- 284 institutional investors held Tandem Diabetes Care (TNDM) as of Q4 2019, up from 273 in Q3 2019.
- Funds reported $3.24B of Tandem Diabetes Care stock for Q4 2019, up 11% quarter-over-quarter.
- 58 funds opened new Tandem Diabetes Care positions in Q4 2019 and 45 closed out, a net change of +13 holders.
- The largest Tandem Diabetes Care buyer in Q4 2019 was Fidelity Investments, an estimated $92.2M added.
- The largest Tandem Diabetes Care seller in Q4 2019 was Renaissance Technologies, an estimated $37.5M sold.
Based on aggregated 13F filings for Q4 2019.